Drug Trial Radar · NCT04330664
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Apr 7, 2020
Primary completion
Jul 29, 2022
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Novartis
- First posted
- Apr 1, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.
Conditions
- Advanced Cancer
- Metastatic Cancer
- Malignant Neoplastic Disease
Interventions
MRTX849Drug
KRAS G12C Inhibitor
TNO155Drug
SHP2 Inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Characterize the safety of MRTX849 and TNO155 in patients having advanced solid tumor malignancies with KRAS G12C mutation.Time frame: 20 months
- Evaluate the pharmacokinetics of MRTX849 and TNO155Time frame: 20 months
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Local Institution - 002-805
Los Angeles, California
Local Institution - 002-803
Orange, California
Local Institution - 002-828
Chicago, Illinois
Local Institution - 002-942
Wichita, Kansas
Local Institution - 002-804
Boston, Massachusetts
Local Institution - 002-808
Boston, Massachusetts
Local Institution - 002-811
Novi, Michigan
Local Institution - 002-809 D
City of Saint Peters, Missouri
Local Institution - 002-809 B
Creve Coeur, Missouri
Local Institution - 002-809 A
St Louis, Missouri
Local Institution - 002-809 C
St Louis, Missouri
Local Institution - 002-809
St Louis, Missouri
Local Institution - 002-809 E
St Louis, Missouri
Local Institution - 002-813
New York, New York
Local Institution - 002-806
New York, New York
Local Institution - 002-801
San Antonio, Texas
Local Institution - 002-810
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.